Siggi Olafsson to step down as Chief Executive
This announcement contains inside information.
London, 24 May 2022 - Hikma Pharmaceuticals PLC (Hikma ) today announces that Siggi Olafsson has resigned as Chief Executive Officer (CEO), and from Hikma's Board of Directors, to pursue other opportunities.
Said Darwazah, Hikma's Executive Chairman and former CEO, will assume all CEO responsibilities, enabling Hikma to continue delivering its strategy. Siggi will remain available to the Group until he departs on 24 June 2022.
Said will continue to work closely with the Executive Committee, including Hikma's three divisional presidents, benefiting from their significant experience and strong management teams. Concurrently, Hikma's Board has initiated an externally facilitated process to identify a new CEO.
Said Darwazah said:
"On behalf of Hikma's Board and the entire Group, I would like to thank Siggi for his leadership over the past four years. Together with the Executive Committee, he has worked tirelessly to drive strategic momentum across all three businesses, especially during the challenging days of the pandemic. Hikma is on a strong footing and well positioned for future growth, and we wish Siggi well for the future".
Siggi Olafsson said:
"It has been a privilege to work for Hikma, and I am proud of what the entire team has achieved during my tenure. I would like to thank the Board for their confidence in me throughout the past four years. I would also like to thank my colleagues around the world for their exceptional hard work and commitment. I believe that Hikma has an exciting future and I look forward to seeing the business go from strength to strength."
-- ENDS -
The person responsible for the release of this announcement on behalf of Hikma is Peter Speirs (Company Secretary).
Enquiries :
Hikma (Investors)
|
Susan Ringdal EVP, Strategic Planning and Global Affairs |
+44 (0)20 7399 2760/ +44 7776 477050 |
|
Guy Featherstone Senior Investor Relations Manager |
+44 (0)20 3892 4389/ +44 7795 896738 |
|
Layan Kalisse Investor Relations Analyst |
+44 (0)20 7399 2788/ +44 7970 709912 |
|
Teneo (Press) Charles Armitstead Camilla Cunningham |
+ 44 (0) 7703 330269 + 44 (0) 7464 982426 |
About Hikma
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/stable Fitch)
Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,700 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com
©2022 Hikma Pharmaceuticals PLC. All rights reserved.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 16 minutes ago CC Japan Income & Growth Trust
- 38 minutes ago 3i Infrastructure
- 43 minutes ago QinetiQ Group
- 1 hour ago JPMorgan Emerging Markets Growth & Income plc
- 1 hour ago National Grid